title: Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update.
authors.affiliation: Department of Cardiology, University Hospital La Timone, Marseille, France. thomascuisset@voila.fr
authors.forename: Thomas
authors.initials: T
authors.lastname: Cuisset
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Harald
authors.initials: H
authors.lastname: Mudra
authors.forename: Olivier
authors.initials: O
authors.lastname: Muller
authors.forename: William
authors.initials: W
authors.lastname: Wijns
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors